Novo Nordisk announced that the FDA has approved the product label update for Victoza (liraglutide [rDNA origin]) to include data showing superior blood sugar control and greater weight reduction when compared to Januvia (sitagliptin; Merck), as well as data demonstrating the safety and efficacy of adding basal insulin to Victoza and metformin for the treatment of adults with type 2 diabetes.
The label update was based on the FDA’s review of two large, randomized, open-label studies in adults with type 2 diabetes. Results showed that patients treated with Victoza experienced greater A1c reductions than Januvia 100mg tablets (both in combination with metformin). In addition, Victoza provided greater weight loss versus patients treated with Januvia.
Victoza, a GLP-1 receptor agonist, was approved in January 2010 as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
For more information call (877) 484-2869 or visit www.victoza.com.